Nintedanib in NSCLC: evidence to date and place in therapy
about
Lung Cancer in Patients with Severe Idiopathic Pulmonary Fibrosis: Critical Aspects.Intrinsic fluorescence of the clinically approved multikinase inhibitor nintedanib reveals lysosomal sequestration as resistance mechanism in FGFR-driven lung cancer.Nintedanib selectively inhibits the activation and tumour-promoting effects of fibroblasts from lung adenocarcinoma patients.
P2860
Nintedanib in NSCLC: evidence to date and place in therapy
description
2016 nî lūn-bûn
@nan
2016 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Nintedanib in NSCLC: evidence to date and place in therapy
@ast
Nintedanib in NSCLC: evidence to date and place in therapy
@en
Nintedanib in NSCLC: evidence to date and place in therapy
@nl
type
label
Nintedanib in NSCLC: evidence to date and place in therapy
@ast
Nintedanib in NSCLC: evidence to date and place in therapy
@en
Nintedanib in NSCLC: evidence to date and place in therapy
@nl
prefLabel
Nintedanib in NSCLC: evidence to date and place in therapy
@ast
Nintedanib in NSCLC: evidence to date and place in therapy
@en
Nintedanib in NSCLC: evidence to date and place in therapy
@nl
P2093
P2860
P356
P1476
Nintedanib in NSCLC: evidence to date and place in therapy
@en
P2093
Angela Listì
Antonio Russo
Eugenio Fiorentino
Francesco Passiglia
Giuseppe Bronte
Nadia Barraco
Sergio Rizzo
Viviana Bazan
P2860
P304
P356
10.1177/1758834016630976
P407
P577
2016-05-01T00:00:00Z